Maintaining Our Moderna FVE Amid Lower Vaccine Guidance
We're maintaining our fair value estimate for Moderna following disappointing third-quarter results and updated COVID-19 vaccine sales guidance.
We're maintaining our fair value estimate for Moderna following disappointing third-quarter results and updated COVID-19 vaccine sales guidance.
We're maintaining our $158 fair value estimate for Moderna (MRNA) following disappointing third-quarter results and updated COVID-19 vaccine sales guidance. Moderna sold 208 million COVID-19 vaccine doses in the third quarter for $4.8 billion, lower than our $7 billion estimate for the quarter, due to a combination of dose release bottlenecks, greater complexity of distribution to more global markets, and lower average global pricing (as more vaccine is delivered to less-developed countries). While some of these sales will be pushed into the fourth quarter or early 2022, we think demand for booster shots could be lower than we had originally anticipated, based on the updated status of Moderna's advance purchase agreements for 2022 and management's discussion of a potential seasonal booster in the U.S. beginning in 2022. We have lowered our sales forecast for Moderna's COVID-19 vaccine to account for a potentially faster transition from a pandemic market to an endemic one, where doses may be reserved for higher-risk populations (including adults over age 65). However, this was countered by our decision to include probability-weighted sales for two rare disease programs in our model; mRNA-3927 (propionic acidemia) and mRNA-3705 (methylmalonic acidemia) have both entered phase 1. While this only adds $500 million in sales to our 2030 projections, the recurring nature of these potential sales is more meaningful to our DCF valuation than temporarily inflated COVID-19 sales. That said, we have only assigned these programs a 25% probability of approval, as proof-of-concept isn't expected until 2022 and intracellular protein targets are considered an unproven, higher-risk modality. Despite Moderna's massive success with its COVID-19 vaccine, we think the changing competitive landscape, virus evolution, and evolving safety and efficacy of its technology beyond COVID-19 create too many questions to grant the firm an economic moat, and we see shares as overvalued at recent prices.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days. |
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.